6 Needs context
A Johns Hopkins study showed that administering sulforaphane glucosinolate (broccoli seed extract) improved symptoms in one-third of autistic children.
"if you give sulforaphane glucosinolate, broccoli seed extract, to the autistic population, they did it at Johns Hopkins, a third of these kids, their brains—and the same thing with the Alzheimer's." (said at 0:22:15)
A landmark pilot randomized, placebo-controlled trial conducted by researchers at Johns Hopkins University School of Medicine and Massachusetts General Hospital evaluated sulforaphane derived from broccoli sprout extract in 44 young males (aged 13–27) with autism spectrum disorder (ASD). In that trial, sulforaphane treatment resulted in a 34% average reduction (improvement) in Aberrant Behavior Checklist (ABC) scores compared to placebo, which is frequently misquoted or conflated as improving one-third of participants. A subsequent randomized trial in children aged 3–12 found small, non-statistically significant improvements on the primary clinician-rated outcome measure, though secondary caregiver ABC ratings did show improvement.
- context: Sulforaphane treatment of autism spectrum disorder (ASD). (Proceedings of the National Academy of Sciences of the United States of America 2014) · cited 459x in the literature
"After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for ABC (P < 0.001, comparing treatments) and 17% for SRS scores (P = 0.017)." (abstract, results, passage verified)
pubmedfull study (doi) - context: Randomized controlled trial of sulforaphane and metabolite discovery in children with Auti… (Molecular autism 2021) · cited 109x in the literature
"Treatment effects on the primary outcome measure, the Ohio Autism Clinical Impressions Scale (OACIS), in the general level of autism were not significant between SF and PL groups at 7 and 15 weeks... Caregiver ratings on secondary outcome measures improved significantly on the Aberrant Behavior Checklist (ABC) at 15 weeks (Cohen's d - 0.96; 95% CI - 1.73, - 0.15), but not on the Social Responsiveness Scale-2 (SRS-2)." (abstract, results)
pubmedfull study (doi)
Low-dose naltrexone inhibits the NLRP3 inflammasome pathway.
"low-dose naltrexone, one of my favorites also for blocking the third pathway, NLRP3 inflammasomes" (said at 0:25:00)
Low-dose naltrexone (and its stereoisomer (+)-naltrexone) attenuates neuroinflammation primarily by antagonizing Toll-like receptors 2 and 4 (TLR2/TLR4) on microglia, which secondarily reduces downstream inflammatory signaling, including the expression of NLRP3 and interleukin-1β (IL-1β). Describing naltrexone as a direct blocker of the NLRP3 inflammasome pathway conflates upstream TLR antagonism with direct NLRP3 inhibition (such as by specific inhibitors like MCC950). Furthermore, support for this mechanism derives from preclinical rodent models rather than human clinical trials.
- context: Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and mem… (Behavioural brain research 2021) · cited 25x in the literature
"This was associated with increased mRNA for hippocampal interleukin-1β (IL-1β), TLR2, TLR4, NLRP3, and IL-17 and elevated expression of the microglial marker Iba1 in CA1 and DG regions of the hippocampus, confirming the neuroinflammation observed in higher-dose EAE models. Importantly, (+)-NTX completely prevented the EAE-induced memory impairments and robustly attenuated the associated proinflammatory effects." (abstract, results, passage verified)
pubmedfull study (doi) - context: Involvement of TLR2-TLR4, NLRP3, and IL-17 in pain induced by a novel Sprague-Dawley rat m… (Frontiers in pain research (Lausanne, Switzerland) 2022) · cited 12x in the literature
"Exploring further mechanisms, we demonstrated that both spinal NOD-like receptor protein 3 (NLRP3) and interleukin-17 (IL-17) are necessary for EAE-induced pain, as intrathecal injections of NLRP3 antagonist MCC950 and IL-17 neutralizing antibody both acutely reversed EAE-induced pain." (abstract, results, passage verified)
pubmedfull study (doi)
A study by Lee et al. found that people not taking dapsone had a rate of Alzheimer's disease six times higher than those taking 100 mg of dapsone.
"So in a study by Lee et al. with like 3 to 4,000 people over 16 years, he gave them 100 milligrams of dapsone, the rates of Alzheimer's were like this, and the people who didn't take dapsone was six times higher." (said at 0:34:25)
A 2022 study by Lee et al. (PMID 35542045) evaluated Alzheimer's disease (AD) diagnoses in South Korean leprosy patients according to dapsone prescription history. The study reported that leprosy patients not prescribed dapsone had significantly higher rates of AD diagnosis compared to those taking dapsone (with an approximate sixfold difference across cohort comparisons). However, the claim frames this as a clinical trial where the author 'gave them 100 milligrams of dapsone' over 16 years, whereas it was a retrospective observational cohort analysis of health insurance and leprosy registry data. Observational studies in this population are subject to substantial confounding by indication, survivorship, and differential healthcare access, and do not establish a causal preventive effect of dapsone in the general population.
- context: Dapsone is an anticatalysis for Alzheimer's disease exacerbation. (iScience 2022) · cited 22x in the literature
"Our study investigated patients with leprosy and AD. They were treated with dapsone (4,4'-diaminodiphenyl sulfone, DDS) as a neuroinflammasome competitor and cGAS/STING pathway inhibitor. Four groups were defined: Treatment (T) 1: DDS prescribed AD diagnosed, T 2: DDS prescribed AD undiagnosed, T 3 DDS unprescribed AD diagnosed, and T 4: DDS unprescribed AD undiagnosed. Dapsone effects on AD can be clearly distinguished according to dapsone presence or absence. T1:T3 proved that the incidence of AD was significantly reduced by dapsone." (abstract, results, passage verified)
pubmedfull study (doi)
Methylene blue is used in the treatment of blood plasma supply to eliminate infectious pathogens.
"in the blood plasma supply when they're treating for all the red blood cells they're storing. Methylene blue is what's used to kill all the infectious agents that's in our blood supply." (said at 0:40:45)
Methylene blue combined with visible light (such as the Theraflex MB-Plasma system) is a well-established pathogen reduction technology used specifically to treat therapeutic plasma units to inactivate viruses and other infectious pathogens. However, the speaker incorrectly asserts that methylene blue is used to treat stored red blood cells or to clear infectious agents from the whole red blood cell supply; methylene blue pathogen inactivation is specific to plasma (and in some systems platelets), whereas red blood cell concentrates require distinct pathogen reduction technologies (such as amustaline/S-303) because methylene blue causes hemolysis or binding issues when applied directly to red blood cells.
Matrix metalloproteinases (MMPs) are elevated when Lyme disease affects the joints.
"Right, like somebody might have Lyme joint pain and their MMP is high, the matrix metalloproteinase is high, it's like, "Okay, that confirms that the Lyme is affecting your joints."" (said at 1:02:24)
Matrix metalloproteinases (such as MMP-1, MMP-3, MMP-10, and MMP-13) are elevated locally in synovial tissue and fluid during Lyme arthritis as part of the host inflammatory response to Borrelia burgdorferi. However, MMP elevation is a non-specific marker of joint inflammation and tissue remodeling seen in many other conditions (including rheumatoid arthritis and osteoarthritis). Serum or synovial MMP testing does not confirm that Lyme disease specifically is the cause of a patient's joint pain.
- supports: Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and m… (Infection and immunity 2005) · cited 70x in the literature
"B. burgdorferi infection significantly induced transcription of MMP-1, -3, -13, and -19 from primary human chondrocyte cells... The synovial fluid levels of MMPs from patients with high and low spirochete burdens were consistent with results seen in the in vitro studies." (abstract, results)
pubmedfull study (doi) - partial: [Usefulness of examinations of serum levels of matrix metalloproteinases 1, MMP-3, MMP-9, … (Przeglad epidemiologiczny 2008) · cited 1x in the literature
"There were no significant differences in serum levels of MMP-3, MMP-9, TIMP-1, HA, anti-CCP between Lyme arthritis patients and patients with arthritic complaints and these parameters are not usefull in differential diagnoses of Lyme arthritis." (abstract, results, passage verified)
pubmed
Sixty percent of Americans have one chronic illness, and 25 percent have two or more.
"60% of Americans have one chronic illness, 25% have two or more, 86% of our health care costs, and 70% is chronic disease." (said at 1:09:01)
The speaker's statement roughly reflects national surveillance data from the Centers for Disease Control and Prevention (CDC), but blends estimates from different definitions of chronic illness. Analyses of the National Health Interview Survey (NHIS) examining 10 major conditions (arthritis, cancer, COPD, coronary heart disease, asthma, diabetes, hepatitis, hypertension, stroke, and kidney disease) found that 51.1% to 51.8% of US adults had at least one condition and 26.4% to 27.2% (roughly 25%) had multiple chronic conditions (two or more). When broader definitions of chronic disease are used, the CDC frequently cites that 6 in 10 (60%) US adults have at least one chronic condition and 4 in 10 (40%) have two or more.
- supports: Prevalence of Multiple Chronic Conditions Among US Adults, 2018. (Preventing chronic disease 2020) · cited 702x in the literature
"More than half (51.8%) of adults had at least 1 of 10 selected diagnosed chronic conditions (arthritis, cancer, chronic obstructive pulmonary disease, coronary heart disease, current asthma, diabetes, hepatitis, hypertension, stroke, and weak or failing kidneys), and 27.2% of US adults had multiple chronic conditions." (abstract, results, passage verified)
pubmedfull study (doi) - context: The Role of Nutrition in Chronic Disease. (Nutrients 2023) · cited 138x in the literature
"According to the Centers for Disease Control and Prevention, six out of every ten adults in the United States have at least one chronic disease, and about four in ten have two or more chronic diseases" (abstract, passage verified)
pubmedfull study (doi) - supports: Prevalence of Multiple Chronic Conditions Among US Adults, 2024. (American journal of public health 2026)
"In 2024, 51.1% of US adults had at least 1 of 10 selected diagnosed chronic conditions, and 26.4% had MCC." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.